Insmed

INSM Large Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 00:03 UTC

$162.43

-1.47% today

52W: $60.40 – $212.75

52W Low: $60.40 Position: 67% 52W High: $212.75

🔗 Compare Brokers Best Broker for Beginners →

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

242.77x

Forward Price/Earnings

P/S Ratio

57.74x

Price-to-Sales

EV/EBITDA

—

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$35B

Market Capitalization

Revenue Growth

152.6%

YoY Revenue Growth

Profit Margin

-210.54%

Net profit margin

ROE

-249.28%

Return on Equity

Beta

1.1

Market sensitivity

Short Interest

5.15%

% of float sold short

Avg. Volume

2,566,490

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Strong Buy

19 analysts

Avg. Price Target

$214.32

+31.95% upside

Target Range

$177.00 – $245.00

★ Smart Money Investors

♣ Druckenmiller

This stock is held by one or more of our 15 tracked Smart Money managers. Click a name to view their full portfolio.

About the Company

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation p

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 1,664 Exchange: NMS